Effects of intradermal lymphocyte therapy in patients with recurrent pregnancy loss: secondary analysis of a randomized controlled trial investigating purinergic signaling, inflammation, and cellular energy status.
Ozkan Yildirim, Habibe Gundogdu, Danial Abbas-Kabiri et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of a randomized controlled trial examined low-dose intradermal lymphocyte therapy (ILT) in 100 patients with recurrent pregnancy loss (RPL), comparing 50 treated patients with 50 receiving routine treatment; 30 women with successful pregnancy histories served as controls. Pregnancy and live birth rates were significantly higher with ILT than routine treatment (p < 0.001). Among patients with successful pregnancy, ILT was also associated with pre- to post-treatment changes in measured cytokines, ATP/AMP ratio, and CD39⁺CD73⁺ cell frequency. The analysis does not establish that these immunometabolic changes mediated the clinical outcomes.
Key findings
- Pregnancy and live birth rates were significantly higher in the ILT group than in the routine-treatment group (p < 0.001).
- In patients with successful pregnancy, ILT recipients showed significant pre- to post-treatment changes across all four measured cytokines.
- Successful-pregnancy patients receiving ILT also had significant changes in ATP/AMP ratio and CD39⁺CD73⁺ cell frequency.
Why it matters
The findings connect a clinical outcome signal with changes in inflammatory markers, purinergic signaling, and cellular energy status in RPL. These measures may help frame further investigation of how ILT relates to pregnancy outcomes, but the reported associations do not show that the biomarker changes explain or cause the apparent clinical benefit.
What to keep in mind
Formal mediation cannot be inferred from this secondary analysis. The abstract reports no effect sizes for pregnancy or live birth rates, limiting assessment of the magnitude of the clinical difference.